FDA Appears Ready To Approve Abiomed's Impella Pumps For Cardiogenic Shock By Mid-Year
This article was originally published in Clinica
Executive Summary
The US FDA will not ask its Circulatory System Devices Panel to review Abiomed’s PMA supplement for a cardiogenic shock indication for its Impella line of ventricular assist devices, according to the company.